Other Events ·
US FDA accepts Sanofi's venglustat for priority review to treat type 3 Gaucher disease
SNYSanofi
Sanofi announced that the US FDA has accepted venglustat for priority review for the treatment of type 3 Gaucher disease.
More from Sanofi
- Sanofi breaks ground on new insulin manufacturing facility in FrankfurtOct 26, 2026
- Sanofi pays Regeneron $1B upfront plus up to $7B in milestones for expanded immunology allianceOct 1, 2026
- Sanofi agrees to divest Lovenox and three sites for a 26.4% stake in CheplapharmSep 17, 2026
- Sanofi halts clinical development of amlitelimab for atopic dermatitis citing lack of meaningful improvement over existing standards of careJul 27, 2026
- FDA approves subcutaneous Sarclisa Escena, first anticancer treatment via on-body injectorJul 17, 2026